Recently, other nAbs, such as human mAbs or Fabs (MERS-27, MERS-GD27, or MCA1), humanized mAbs (hMS-1, 4C2 h), mouse mAbs (Mersmab1, 4C2, or D12), single-domain antibodies (nanobodies Nbs) HCAb-83 or NbMS10-Fc and transchromosomic cattle antibody SAB-301 recognizing epitopes on the RBD have been demonstrated to neutralize pseudotyped and/or live MERS-CoVs [31]. Only SAB-301 is under phase I clinical trial [72].